Skip to main content
Skip to footer
Home
About
About
Management
Board of Directors
Scientific-Medical
Advisory Board
Company Values
Pipeline
Pipeline
Vidofludimus Calcium
IMU-856
IMU-381
News
News Releases
Photo Corner
Video Corner
Publications
Investors
IR Home
News Releases
Events and Presentations
Stock Information
Financials and SEC Filings
Corporate Governance
IR Contact
Career
Contact
Home
About
About
Management
Board of Directors
Scientific-Medical
Advisory Board
Company Values
Pipeline
Pipeline
Vidofludimus Calcium
IMU-856
IMU-381
News
News Releases
Photo Corner
Video Corner
Publications
Investors
IR Home
News Releases
Events and Presentations
Stock Information
Financials and SEC Filings
Corporate Governance
IR Contact
Career
Contact
IMU-856: Phase 1 SAD/MAD Data in Healthy Human Subjects
Tuesday, September 20, 2022
Presentation IMU-856 SAD/MAD Data 2022
Play Recording IMU-856 SAD/MAD Data 2022
Next Post
B & T Cell-Mediated Autoimmune Disease Drug Development Summit
Safety and Efficacy of Vidofludimus Calcium in Patients Hospitalized with COVID-19: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial
Home – 2
About
Pipeline
News
Publications
Investors
Career
Contact
Management
Board of Directors
Scientific-Medical
Advisory Board
Company Values
Vidofludimus Calcium
IMU-856
IMU-381
IR Home
News Releases
Events and Presentations
Stock Informations
Financials and SEC Filings
Corporate Governance
IR Contact
Search
Search
